Jump to content

BLT


colaiscute

Recommended Posts

  • Replies 10k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

Thanks Diana. This is a really good acquisition. Pfizer would have spent at least $10-12M in R&D on TT-034 and we get that for next nothing. When the first results come through from the clinic the MC for BLT will soar and more than make up for the dilution.

 

I would like to know how much cash in bank is left over from the Pfizer days as this could be quite cash positive for BLT as not all of the Tacere management team are coming over and so the overheads will be significantly reduced. Effectively, the team at Tacere will be trading their cash for future royalties. All good for BLT.

Link to comment
Share on other sites

Yes. It would seem that Tacere have made a long term decision ... only way to go with new technology. The possibilities for gene silencing technology are mind bogglingly massive. There are many disease states that could be sorted out, but I am no technical expert so I leave that to others. Suffice to say that I've been here for a long time and cannot understand why the technology has not moved along far more quickly than it has. Let's hope this move will pick up the pace in the future.

R/Di

Link to comment
Share on other sites

hmmm, $1.5M in stock? thats the best Tacere could do?

oh dear, i cant help think the result will be more capital raisings for BLT, and soon

 

but with todays announcement following the hypo-allergenic milk development I am intrigued by the example of scientific development for commercialization Plastic provided in his post before it was deleted. He referred to nuclear power, the splitting of the atom with regards to the relationship it has to "heavy" water. That is water carrying a hydrogen isotope with a mass greater than one.

 

I actually see a lot of similarities between differing isotopes of any particular element and what is happening in the RNAi space at the moment. Because just as an isotope differs from others in its element by the number of neutrons all the different RNAi references, while confusing and sound distinct from each other are all part of the same larger pie (element), yet differentiated from each other by the features of the oligonucleotide or the target area of the cell. This seperation of features is what all the patent wars have been about. If we assume that to be correct, then the case study of nuclear power provides guidance to those who aren't scientists but do know a bit of history and commerce.

 

For example, while heavy water makes nuclear power possible, without it you can't create nuclear power, whether you have split the atom or not. It is completely useless if you have not yet split the atom. But even after you have married the two, there are still many different processes, materials, systems and structures that need to be designed and created before you can put power out on to the grid to someones house and charge them for it according to their meter usage. ie. put product in to market.

 

So there first has to be a primary discovery before there can be secondary, tertiary and other discoveries made. Only then can you can meet a commercial need. In the case of BLT that is curing a disease in man.

 

So after following this thread for a long time, and watching recent developments, especially the hypo-allergenic milk one, and not the least being Monsanto and ALNY going to ISIS to get their FTO, I am unconvinced BLT is what a lot of people think it is. I believe it is a differentiated heavy water company. Or a secondary down-stream discovery from the primary discovery of miRNA signalling which at this point of time, with information available leads me to conclude belongs to ssRNAi, ISIS and Regulus.

 

The paper on Daisy the cow, indicates as much. The tool they used from Invitrogen was all about using ssRNAi and antisense to effect a double stranded hairpin reaction within the cell. What Pannobhaso tried to ridicule Plastic on is an enhancement only. That is something that makes something better than it already is. Maybe Pannobhaso would care to explain that one since he was so sure the stem and internal loop structures belonged to BLT and without these structures, the whole thing wouldn't work.

 

Whether it enhances or facilitates the gene silencing is moot. The point is, it is not the primary discovery. Rendering it useless by itself. Just as the case with nuclear power and heavy water. Which will explain why Mark Kay's mice died of toxicity issues and the un-documented non-human primates mentioned on InvestorVillage are just as dead.

 

This may well be the reason why BLT have been able to buy back Tacere. In the end, with or without the might of PFE, they ended up with something that just didn't work. They needed their FTO with ssRNAi and maybe ISIS wouldn't let them have one. That sure would explain why PFE stalled on the money front.

 

But the good news is, as Plastic says, if BLT were to takeover ALNY either directly or through RXi, they would end up with the Regulus stake belonging to ALNY and then we would have a marriage made in heaven with critical IP holders coming together to effect gene silencing and starting the beginning of the end to commercialization of the scientific discovery that is miRNA signalling and to getting product in market. Whether that product is food, fuel, textiles or drugs.

 

Further, if we consider BLT as a Tier Two company in the RNAi space, then it also carries a B-grade status due to the ursury and prior art claims put on it by CSIRO.

 

Thus the bad news is, there is no guarantee a BLT shareholder will do well considering the history and directors of this company.

 

So it pays to beware of false prophets and their shibboleths.

 

Currently I am trying to buy Regulus. It is said, had an investor put $1000 in to Microsoft at the time of its IPO, in ten years time that person would've been a millionaire. I beleive the same will happen with Regulus.

 

Pannobhaso, you are clearly a clever man with your science background. I would like you to rise to the challenge and venture on to the InvestorVillage ISIS thread with Plastic and make your claims there about BLT and ddRNAi. There are many scientists and academics there with whom you could have a more rigorous debate on the merits of your claims.

 

 

:graduated:

Link to comment
Share on other sites

Rubra or should I say plastic for there could not be two people who clearly want to mis-quote me in an identical fashion i.e., throw in a reference to Regulus where there was none before in my statement that the low allergic milks science is not antisense technology or ssrna, I have no interest in ISIS and no interest in the Investor Village ISIS thread. You used this thread as your reference to the "anecdotal evidence" that Gradalis had safety problems and in fairness to you I did click on the link you provided but it did not lead to any such evidence. It only linked to the ISIS thread with hundreds of posts. No evidence at all. That was pretty much what I expected from someone who clearly has no idea what they are talking about.

 

Don't get me wrong. I don't mind that you don't have a clue about the subject matter. What I object to is you trying to fool others into believing you, especially when you are using the BLT thread as a platform to perpetrate the deception. Leave the BLT thread to those interested in BLT or at least making informed and educated comments about it.

 

The disguise did not work and FYI Regulus is an miRNA company and not ssRNA or an antisense company so while you are pumping up its tires you're puncturing holes those of your hobbyhorse ISIS.

Link to comment
Share on other sites

hmmm, $1.5M in stock? thats the best Tacere could do?

Well, if TT-034 is successful in Phase I, then I think we could safely say that BLT should have a market cap of more than $1B. After all, BMS paid $2.5B for Inhbitex for the failed HCV drug that had not yet entered into phase II.

 

That $1.5M in stock would suddenly be worth @ $100M and up to 35% in royalties. Sounds better than the deal with Pfizer.

 

BLT have all the patents they need to get both the HCV and the pain program to commercialisation. BLT is a tier 2 RNAi company in market cap only.

 

Doesn't mean there will not be tears along the way of course, especially when money is so hard to find and a capital raising is certainly not out of the question. But, this is a high risk play and I think that most shareholders would be aware of that.

Link to comment
Share on other sites

"$1.5M in stock would suddenly be worth @ $100M and up to 35% in royalties"

 

and why didnt Pfizer want it again?

they have been quite active doin deals

 

and just why would Tacere sell the kitchen sink for $1.5M in stock that was about to be diluted like cordial?

surely there were many partnering options for Tacere, they just want to be with BLT and hate cash

gatekeeper and keymaster

 

and why did sue leave to PGL?

 

at least bridges has a history of delivering big

 

roll out the chief business officer, with some famous quotes, we need capital

:devilsmiley:

Link to comment
Share on other sites

rubra, I don't know the answers to your questions I'm afraid. But I too wonder why Pfizer didn't have enough confidence to proceed after getting it to such a stage. Seems strange. Perhaps they thought that Gilead and BMS had it covered. Perhaps they thought they saw something they didn't like. But if they did, and let the compound go, wouldn't they have espressed concerns about the safety or lack of effeciency? Perhaps they thought that gene therapy (and ddRNAi by default) would never be considered by the FDA. A few things have changed since they gave TT-034 back: The fasttrack bill has been passed; the first gene therapy drug in Europe is likely to be given the go-ahead; Inhibitex's drug was canned; and Pharmasset's drug has shown to be unsuccessful in certain strains of HCV.

 

I guess only BLT and Tacere and the other party involved know whether there is a deal in the pipeline or whether a capital raising is in the wind. I guess we will know one way or another shortly. In any case, I am more positive about the company's prospects than what I was yesterday and at least we are seeing some action, rather than just watching the sp go in a backward direction.

 

I just don't understand why people come to these forums, after reasonably good news and bash the heck out of it, and try to promote their other holdings at the same time.

Link to comment
Share on other sites

I could be wrong but I thought the news at the time of the Pfizer closure was that the Sandwich site was to be sold and only about 600 staff out of well over 2,000 were to remain there until their R&D work was completed. Then they too would be made redundant.

 

The completion of the pre-clinical work by Tacere/Pfizer was an obvious cut-off point and unfortunately coincided exactly with Pfizer's decision to close its UK R&D site. Clearly, with nearly 2,000 jobs lost it was more than just TT-034 that got the chop.

 

Cann't wait for Pl results as the HCV field has seen some big $ get thrown at early clinical stage companies.

 

The employment of David Suhy will undoubtedly speed up our HBV program and that could prompt another Chinese pharma to take an interest in BLT. Maybe Biomics will get a share of the Chinese government's R&D $ and increase its stake in the program?

 

There is now just one piece of the jigsaw left to put in place and that is how to fund the next stage of the company's development. I hope the involvement of Lodge Partners is not an indication of how funds will be raised but if that is the only way then so be it.

Link to comment
Share on other sites

Casey Analyst Forecasts Explosive Biotech Growth

 

http://jutiagroup.com/20121011-casey-analy...biotech-growth/

 

 

ItÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ll start with a trickle, more than a flood. But make no mistake: RNAi, or

temporary gene silencing through interference with the messenger RNA that signal

cell behavior, looks to be one of the most important genetic treatment

methodologies yet conceived.

Genetics are at the root of just about every major chronic diseaseÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâہ¡ÃƒÆ’‚ÂÂheart disease, cancer, diabetes. Gene silencing has serious promise with regard to controlling the root causes and predispositions for some of these maladies, instead of waging continuous battles against symptoms, as we do today.

 

 

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...